openPR Logo
Press release

Global Alzheimer’s disease (AD) Market to 2024

11-14-2017 05:48 PM CET | Health & Medicine

Press release from: Optima insinghts pvt ltd

/ PR Agency: optima Insights
Alzheimer?s disease , Pathophysiology, Disease Burden and Economic Impact

Alzheimer?s disease , Pathophysiology, Disease Burden and Economic Impact

Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions

Global Alzheimer’s disease (AD) market was valued at $3.1bn in 2015 and is forecast to grow at a modest 5.3% CAGR between 2015 and 2024, to reach 2024 global sales of $5.2bn. AD is an irreversible, progressive brain disease that slowly destroys memory and, eventually even the ability to carry out the simplest tasks of daily living.

AD afflicts over 15 million people worldwide with roughly 5 million people in the U.S. are living with this disease. It is estimated that 10% of people aged 65 and older, and about 50% of people over 85, suffer from AD. Direct medical and indirect costs associated with AD are high. In the U.S. alone, the health care expenses and lost wages due to AD is estimated at $100bn annually. With life expectancy increasing throughout the world, AD is expected to become a global health care challenge.

Alzheimer's disease (AD) remains an unmet need and a multi-billion dollar opportunity for the pharmaceutical industry. The amyloid-beta (Aß) hypothesis remains they key target for pharmacological intervention that seek to slow down disease progression. Plaques and tangles in the brain are two of the main features of Alzheimer’s disease. This is followed by the loss of connections between neurons in the brain. Recent clinical trials demonstrated that development of new anti-Aβ antibodies is necessary to provide clinical benefits to AD patients.

“Treatment Algorithm”

Currently only symptomatic treatments exist, Acetylcholinesterase inhibitors remain the mainstay treatment option in the AD market and are expected to dominate the market for the next few years, despite limited therapeutic benefits. Pfizer’s Aricept continue to be the acetylcholinesterase inhibitor of choice in the treatment of AD. Novartis and Allergan have leading market share positions in branded products in this category. Glutaminergic modulators also play a role in memory and cognition, signaling through the NMDA receptor. This class is led by Allergan’s Namenda XR. Glutaminergic modulators and acetylcholinesterase inhibitors are often used in combination with one another.

Generics of the cholinesterase inhibitors will likely to capture significant share of the Alzheimer’s treatment market through 2024.

“Product innovations in AD treatment”


The exact cause of AD is unknown, but genetics and environmental factors appear to play a role. Researchers continue to work on the biological mechanisms of AD, leading the way for the development of novel therapies.
Agents with potential disease-modifying characteristics are advancing to Phase III programs using the latest PET imaging technology and biomarkers. Late-stage trials continue to target slowing the disease progression in patients with mild or moderate AD. Experts continue to believe that beta-amyloid targeting agents in AD with the earliest forms of the disease may ultimately yield the greatest efficacy benefit.

Candidates entering Phase III studies are learning from the series of prior Phase III failures in the field. Key clinical trial failures of the recent past include among others
Eli Lilly’s semagacestat, Pfizer/J&J/Elan’s bapineuzumab, Myriad’s Flurizan,and Pfizer/Medivation’s Dimebon.

Next-Generation treatments are primarily focused on beta-amyloid field. Researchers believe that the build-up of beta-amyloid in the brain may be the cause of Alzheimer’s disease. The treatment strategies targeting beta-amyloid include immunotherapy, monoclonal antibodies, therapeutic vaccines, secretase inhibitors (gamma and beta), and aggregation inhibitors.

Tau-based therapies and a number of novel mechanisms of actions including 5-HT6 receptor approach are also being evaluated in the treatment of AD.

Approved Treatments in AD

Full Report : http://optimainsights.org/request-toc/global-alzheimer-s-disease-ad-market-to-2024

"Pfizer, Eisai, J&J, Shire, Allergan, and Novartis are some of the key players for AD Treatment market"

Key players in the AD treatment include Pfizer, Eisai, J&J, Allergan, and Novartis among others.

Currently available AD treatments from these companies provide only symptomatic relief, temporarily improving brain function in patients with mild-to-moderate disease. These treatments include acetylcholinesterase inhibitors from Pfizer/Eisai’s Aricept, J&J/Shire’s Razadyne ER, Novartis’ Exelon and Allergan’s Nemenda.

There is a range of disease modifying next generation treatments being developed in AD. For example, Eli Lilly is clinically testing solanezumab in EXPEDITION 3 and if approved in by 2017, it will capture a substantial portion of the AD market by 2024, offering substantial growth to its top line.

Merck’s verubecestat, a beta secretase inhibitor is in two phase III trials EPOCH and APECS. EPOCH investigates the efficacy of verubecestat in mild-to-moderate AD patients and has a primary completion date in 2017. Biogen has advanced aducanumab into a Phase III program (EMERGE and ENGAGE) with expected data from these trials to be available in 2019. AstraZeneca is also advancing products in beta secretase Inhibitor through clinical trials.

Table of Contents

Chapter 1: Methodology and Scope

Research Methodology
Segmentations
Research Scope & Assumptions
Market Definition
Chapter 2: Disease Backdrop & Patient Potential

Executive Summary

2.1 Alzheimer’s disease 101

2.2 Etiology

2.3 Pathophysiology

2.4 Disease Burden and Economic Impact

2.5 Healthcare Expenditure (U.S., Top 5 EU and Japan)

2.6 Current Prevalence, Incidence, Risk & Co-Morbidities (U.S., Top 5 EU and Japan)

2.7 Forecast Prevalence, Incidence, Risk & Co-Morbidities (U.S., Top 5 EU and Japan)

Our Seriveces : http://optimainsights.org/services

Optima Insights is an innovative research and insights driven enterprise committed to offer actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content holds the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them take better business decisions towards attaining market leadership.

Chakradhar G
Manager International Marketing
---------------------------------
1 MMC, Road, Chennai. Pin - 600060,
Tamil Nadu, I N D I A
Phone: +91 966 6620 365
Whatsapp: +91 966 6620 365
Email: info@optimainsights.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Alzheimer’s disease (AD) Market to 2024 here

News-ID: 816627 • Views: 377

More Releases from Optima insinghts pvt ltd

Head & Neck Cancer Treatment Market Outlook to 2022
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions Details Report : http://optimainsights.org/request-toc/head-neck-cancer-treatment-market-outlook-to-2022 Highlights Key Insights Addressed: - Defining market size from 2013 to 2015. Estimating
Advanced Wound Care Market Outlook to 2024
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions Details Services : http://optimainsights.org/services The global advanced wound care market was valued at $12.5bn in 2015 and is forecast to grow at CAGR of 4.7%
Lung Cancer Treatment Market Outlook to 2022
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions The global lung cancer drugs market was valued at $3.1bn in 2016 and is forecast to grow at a healthy 31.1% CAGR between 2016
Breast Cancer Treatment Market Outlook to 2022
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions. Table of Contents Chapter 1 Methodology and Scope Research Methodology Segmentation Research Scope & Assumptions Market Definition Chapter 2: Disease Backdrop & Patient Potential

All 5 Releases


More Releases for Alzheimer

Alzheimer Disease Drugs Market Global Trends, Market Share, Industry Size, Growt …
Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently
Anti-β-Alzheimer Therapies Market Analysis with Technological Advancement and G …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as